Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CD20-SN-38
- Development stage
- Preclinical
- Lead developer
- National Cancer Center Japan
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
**anti-CD20-SN-38** is a nonproprietary, preclinical anti-CD20 antibody-drug conjugate descriptor rather than a uniquely identified clinical drug product. In the cited research construct, an anti-CD20 monoclonal antibody was coupled through a polyethylene glycol carbamate linker to SN-38, the active topoisomerase I-inhibitory metabolite of irinotecan. Following CD20-mediated cellular uptake, intracellular carboxylesterase activity was reported to release SN-38, producing antitumor activity in malignant lymphoma models. The precise antibody clone and proprietary development identifier were not specified in the supplied publication. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7657259/))
- Other names
- anti-CD20 mAb-PEG-SN-38anti-CD-20 mAb-PEG-SN-38anti-CD 20 mAb-PEG-SN-38
02
Targets
CD20 (B-lymphocyte antigen CD20)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on anti-CD20-SN-38.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CD20-SN-38.